Cardiac amyloidosis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(4 intermediate revisions by one other user not shown)
Line 4: Line 4:


==Overview==
==Overview==
The presence or absence of cardiac involvement with amyloid is the most important prognostic factor.<ref name="pmid10319082">{{cite journal |author=Gertz MA, Lacy MQ, Dispenzieri A |title=Amyloidosis: recognition, confirmation, prognosis, and therapy |journal=[[Mayo Clinic Proceedings. Mayo Clinic]] |volume=74 |issue=5 |pages=490–4 |year=1999 |month=May |pmid=10319082 |doi=10.4065/74.5.490 |url=http://linkinghub.elsevier.com/retrieve/pii/S0025-6196(11)65130-6 |accessdate=2012-02-13}}</ref> Untreated cardiac amyloidosis is associated with a very poor prognosis and a high mortality rate. The most common cardiac complications include [[heart failure]], [[sudden cardiac death]] due to [[electromechanical dissociation]] and [[pericardial effusion]].
The presence or absence of cardiac involvement with amyloid is the most important prognostic factor. Untreated cardiac amyloidosis is associated with a very poor prognosis and a high mortality rate. The most common cardiac complications include [[heart failure]], [[sudden cardiac death]] due to [[electromechanical dissociation]] and [[pericardial effusion]].


==Natural History==
==Natural History, Complications, and Prognosis==
Untreated cardiac amyloidosis is associated with high rate of cardiac complications and eventually death. Cardiac involvement in [[AL amyloidosis]] is associated with a higher mortality rate compared with that in [[senile amyloidosis]] and [[familial forms of amyloidosis]]. Also, [[heart failure]] in [[AL type amyloidosis]] of the heart is more difficult to treat as compared with that associated with [[TTR type amyloid]].


==Complications==
=== Natural History ===
 
* Untreated cardiac amyloidosis is associated with high rate of [[Heart|cardiac]] [[Complication (medicine)|complications]] and eventually death.
* Cardiac involvement in [[AL amyloidosis]] is associated with a higher [[mortality rate]] compared with that in [[senile amyloidosis]] and [[Familial amyloidosis|familial forms of amyloidosis]].<ref name="pmid10319082">{{cite journal |author=Gertz MA, Lacy MQ, Dispenzieri A |title=Amyloidosis: recognition, confirmation, prognosis, and therapy |journal=[[Mayo Clinic Proceedings. Mayo Clinic]] |volume=74 |issue=5 |pages=490–4 |year=1999 |month=May |pmid=10319082 |doi=10.4065/74.5.490 |url=http://linkinghub.elsevier.com/retrieve/pii/S0025-6196(11)65130-6 |accessdate=2012-02-13}}</ref>
* Also, [[heart failure]] in [[AL type amyloidosis]] is more difficult to treat as compared with that associated with TTR type amyloid.
 
===Complications===
The following are the complications of cardiac amyloidosis:
The following are the complications of cardiac amyloidosis:
* [[Congestive heart failure]]<ref name="pmid23391947">{{cite journal |author=Shah S, Dungu J, Dubrey SW |title=Senile cardiac amyloidosis: an underappreciated cause of heart failure |journal=[[BMJ Case Reports]] |volume=2013 |issue= |pages= |year=2013 |pmid=23391947 |doi=10.1136/bcr-2012-007635 |url=}}</ref><ref name="pmid23474361">{{cite journal |author=Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz MA |title=Left ventricular device implantation for advanced cardiac amyloidosis |journal=[[The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation]] |volume=32 |issue=5 |pages=563–8 |year=2013 |month=May |pmid=23474361 |doi=10.1016/j.healun.2013.01.987 |url=}}</ref>
* [[Congestive heart failure]]<ref name="pmid23391947">{{cite journal |author=Shah S, Dungu J, Dubrey SW |title=Senile cardiac amyloidosis: an underappreciated cause of heart failure |journal=[[BMJ Case Reports]] |volume=2013 |issue= |pages= |year=2013 |pmid=23391947 |doi=10.1136/bcr-2012-007635 |url=}}</ref><ref name="pmid23474361">{{cite journal |author=Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz MA |title=Left ventricular device implantation for advanced cardiac amyloidosis |journal=[[The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation]] |volume=32 |issue=5 |pages=563–8 |year=2013 |month=May |pmid=23474361 |doi=10.1016/j.healun.2013.01.987 |url=}}</ref>
* [[Sudden cardiac death]] ([[SCD]])<ref name="pmid22301727">{{cite journal |author=Edler C, Saeger W, Orth U, Braun C, Wulff B, Sperhake J |title=[Hereditary cardiac amyloidosis with transthyretin mutations. A cause of sudden death ] |language=German |journal=[[Herz]] |volume=37 |issue=4 |pages=456–60 |year=2012 |month=June |pmid=22301727 |doi=10.1007/s00059-011-3566-9 |url=}}</ref> is largely due to [[electromechanical dissociation]] unlike other disease states where [[sudden cardiac death]] is predominantly due to other causes such as [[ventricular arrhythmia]].
* [[Sudden cardiac death|Sudden cardiac death (SCD)]]<ref name="pmid22301727">{{cite journal |author=Edler C, Saeger W, Orth U, Braun C, Wulff B, Sperhake J |title=[Hereditary cardiac amyloidosis with transthyretin mutations. A cause of sudden death ] |language=German |journal=[[Herz]] |volume=37 |issue=4 |pages=456–60 |year=2012 |month=June |pmid=22301727 |doi=10.1007/s00059-011-3566-9 |url=}}</ref>  
**Largely due to [[electromechanical dissociation]]; unlike other disease states where [[sudden cardiac death]] is predominantly due to other causes such as [[ventricular arrhythmia]]
* [[Myocardial infarction]]<ref name="pmid21747665">{{cite journal |author=Mugnai G, Cicoira M, Rossi A, Vassanelli C |title=Syncope in cardiac amyloidosis and chronic ischemic heart disease: A case report |journal=[[Experimental and Clinical Cardiology]] |volume=16 |issue=2 |pages=51–3 |year=2011 |pmid=21747665 |pmc=3126684 |doi= |url=}}</ref>
* [[Myocardial infarction]]<ref name="pmid21747665">{{cite journal |author=Mugnai G, Cicoira M, Rossi A, Vassanelli C |title=Syncope in cardiac amyloidosis and chronic ischemic heart disease: A case report |journal=[[Experimental and Clinical Cardiology]] |volume=16 |issue=2 |pages=51–3 |year=2011 |pmid=21747665 |pmc=3126684 |doi= |url=}}</ref>
* [[Pericardial effusion]]<ref name="pmid7091168">{{cite journal |author=Brodarick S, Paine R, Higa E, Carmichael KA |title=Pericardial tamponade, a new complication of amyloid heart disease |journal=[[The American Journal of Medicine]] |volume=73 |issue=1 |pages=133–5 |year=1982 |month=July |pmid=7091168 |doi= |url=}}</ref>
* [[Pericardial effusion]]<ref name="pmid7091168">{{cite journal |author=Brodarick S, Paine R, Higa E, Carmichael KA |title=Pericardial tamponade, a new complication of amyloid heart disease |journal=[[The American Journal of Medicine]] |volume=73 |issue=1 |pages=133–5 |year=1982 |month=July |pmid=7091168 |doi= |url=}}</ref>
* [[Cardiac tamponade]]<ref name="pmid1428240">{{cite journal |author=Navarro JF, Rivera M, Ortuño J |title=Cardiac tamponade as presentation of systemic amyloidosis |journal=[[International Journal of Cardiology]] |volume=36 |issue=1 |pages=107–8 |year=1992 |month=July |pmid=1428240 |doi= |url=}}</ref> It should be noted, however, that the classic echocardiographic signs of [[cardiac tamponade]], such as [[right atrial indentation]] and [[right ventricular compression]], are not seen in [[cardiac tamponade]] associated with cardiac amyoidosis due to the stiffness of the atrial and ventricular walls. Therefore a high degree of suspicion should be maintained in patients with heart failure and a mild to moderate [[pericardial effusion]]. <ref name="pmid7091168">{{cite journal |author=Brodarick S, Paine R, Higa E, Carmichael KA |title=Pericardial tamponade, a new complication of amyloid heart disease |journal=[[The American Journal of Medicine]] |volume=73 |issue=1 |pages=133–5 |year=1982 |month=July |pmid=7091168 |doi= |url=}}</ref>
* [[Cardiac tamponade]]<ref name="pmid1428240">{{cite journal |author=Navarro JF, Rivera M, Ortuño J |title=Cardiac tamponade as presentation of systemic amyloidosis |journal=[[International Journal of Cardiology]] |volume=36 |issue=1 |pages=107–8 |year=1992 |month=July |pmid=1428240 |doi= |url=}}</ref>
**It should be noted, however, that the classic echocardiographic signs of [[cardiac tamponade]], such as [[right atrial indentation]] and [[right ventricular compression]], are not seen in [[cardiac tamponade]] associated with cardiac amyloidosis due to the stiffness of the atrial and ventricular walls. Therefore a high degree of suspicion should be maintained in patients with heart failure and a mild to moderate [[pericardial effusion]].<ref name="pmid7091168">{{cite journal |author=Brodarick S, Paine R, Higa E, Carmichael KA |title=Pericardial tamponade, a new complication of amyloid heart disease |journal=[[The American Journal of Medicine]] |volume=73 |issue=1 |pages=133–5 |year=1982 |month=July |pmid=7091168 |doi= |url=}}</ref>
* [[Valvular heart diseases]], with [[aortic stenosis]] being the most common followed by [[mitral regurgitation]]
* [[Valvular heart diseases]], with [[aortic stenosis]] being the most common followed by [[mitral regurgitation]]
* [[Atrial fibrillation]]<ref name="pmid11416540">{{cite journal |author=Yunis NA, Petrasko MS, Cannistra LB |title=An Elderly Man With Progressive Dyspnea on Exertion and Atrial Fibrillation as Manifestations of Senile Cardiac Amyloidosis |journal=[[The American Journal of Geriatric Cardiology]] |volume=9 |issue=2 |pages=69–72 |year=2000 |month=March |pmid=11416540 |doi= |url=}}</ref>
* [[Atrial fibrillation]]<ref name="pmid11416540">{{cite journal |author=Yunis NA, Petrasko MS, Cannistra LB |title=An Elderly Man With Progressive Dyspnea on Exertion and Atrial Fibrillation as Manifestations of Senile Cardiac Amyloidosis |journal=[[The American Journal of Geriatric Cardiology]] |volume=9 |issue=2 |pages=69–72 |year=2000 |month=March |pmid=11416540 |doi= |url=}}</ref>
Line 21: Line 28:
* [[Ventricular arrhythmia]]s<ref name="pmid20061577">{{cite journal |author=Lin G, Dispenzieri A, Brady PA |title=Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death |journal=[[European Heart Journal]] |volume=31 |issue=12 |pages=1538 |year=2010 |month=June |pmid=20061577 |doi=10.1093/eurheartj/ehp592 |url=}}</ref>
* [[Ventricular arrhythmia]]s<ref name="pmid20061577">{{cite journal |author=Lin G, Dispenzieri A, Brady PA |title=Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death |journal=[[European Heart Journal]] |volume=31 |issue=12 |pages=1538 |year=2010 |month=June |pmid=20061577 |doi=10.1093/eurheartj/ehp592 |url=}}</ref>
* [[Sick sinus syndrome]] (occasionally)
* [[Sick sinus syndrome]] (occasionally)
* [[Heart block]]s and other conduction defects. Higher degree blocks are unusual in cardiac amyloidosis associated with [[AL type amyloidosis]], but in the TTR type progressive conduction system disease is common and requires pacemaker implantation. Frequently, the electrophysiologic function appears to be abnormal in the His-Purkinje system. Prolonged infra-His conduction time is an independent predictor of [[sudden death]] in these patients. <ref name="pmid9316537">{{cite journal |author=Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH |title=Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement |journal=[[Journal of the American College of Cardiology]] |volume=30 |issue=4 |pages=1046–51 |year=1997 |month=October |pmid=9316537 |doi= |url=}}</ref>
* [[Heart block]]s and other conduction defects  
**Higher degree blocks are unusual in cardiac amyloidosis associated with [[AL type amyloidosis]], but in the TTR type, progressive conduction system disease is common and requires pacemaker implantation. Frequently, the electrophysiologic function appears to be abnormal in the His-Purkinje system. Prolonged infra-His conduction time is an independent predictor of [[sudden death]] in these patients. <ref name="pmid9316537">{{cite journal |author=Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH |title=Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement |journal=[[Journal of the American College of Cardiology]] |volume=30 |issue=4 |pages=1046–51 |year=1997 |month=October |pmid=9316537 |doi= |url=}}</ref>
* [[Syncope]] or [[presyncope]]<ref name="pmid21747665">{{cite journal |author=Mugnai G, Cicoira M, Rossi A, Vassanelli C |title=Syncope in cardiac amyloidosis and chronic ischemic heart disease: A case report |journal=[[Experimental and Clinical Cardiology]] |volume=16 |issue=2 |pages=51–3 |year=2011 |pmid=21747665 |pmc=3126684 |doi= |url=}}</ref>
* [[Syncope]] or [[presyncope]]<ref name="pmid21747665">{{cite journal |author=Mugnai G, Cicoira M, Rossi A, Vassanelli C |title=Syncope in cardiac amyloidosis and chronic ischemic heart disease: A case report |journal=[[Experimental and Clinical Cardiology]] |volume=16 |issue=2 |pages=51–3 |year=2011 |pmid=21747665 |pmc=3126684 |doi= |url=}}</ref>
* Increased sensitivity to [[digoxin]] with the potential for digoxin toxicity and related arrhythmias. The amyloid protein tends to bind the digoxin and increase its local concentration in the conduction system for instance.
* Increased sensitivity to [[digoxin]] with the potential for [[digoxin toxicity]] and digoxin related arrhythmias
**The amyloid protein tends to bind the digoxin and increase its local concentration in the conduction system for instance.
* [[Ascites]] ([[fluid accumulation in the abdomen]])
* [[Ascites]] ([[fluid accumulation in the abdomen]])
* [[Stroke]] and [[claudication]] due to [[intracardiac thrombus]] causing [[thromboembolism]].<ref name="pmid19414641">{{cite journal |author=Feng D, Syed IS, Martinez M, ''et al.'' |title=Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis |journal=[[Circulation]] |volume=119 |issue=18 |pages=2490–7 |year=2009 |month=May |pmid=19414641 |doi=10.1161/CIRCULATIONAHA.108.785014 |url=}}</ref><ref name="pmid17984380">{{cite journal |author=Feng D, Edwards WD, Oh JK, ''et al.'' |title=Intracardiac thrombosis and embolism in patients with cardiac amyloidosis |journal=[[Circulation]] |volume=116 |issue=21 |pages=2420–6 |year=2007 |month=November |pmid=17984380 |doi=10.1161/CIRCULATIONAHA.107.697763 |url=}}</ref> Risk factors include:
* [[Stroke]] and [[claudication]] due to [[intracardiac thrombus]] causing [[thromboembolism]].<ref name="pmid19414641">{{cite journal |author=Feng D, Syed IS, Martinez M, ''et al.'' |title=Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis |journal=[[Circulation]] |volume=119 |issue=18 |pages=2490–7 |year=2009 |month=May |pmid=19414641 |doi=10.1161/CIRCULATIONAHA.108.785014 |url=}}</ref><ref name="pmid17984380">{{cite journal |author=Feng D, Edwards WD, Oh JK, ''et al.'' |title=Intracardiac thrombosis and embolism in patients with cardiac amyloidosis |journal=[[Circulation]] |volume=116 |issue=21 |pages=2420–6 |year=2007 |month=November |pmid=17984380 |doi=10.1161/CIRCULATIONAHA.107.697763 |url=}}</ref>  
**[[Atrial fibrillation]]
**Risk factors include:
** Atrial dysfunction due to infiltration of the atria by [[amyloid]]
***[[Atrial fibrillation]]
** Left ventricular [[diastolic dysfunction]]
*** Atrial dysfunction due to infiltration of the atria by [[amyloid]]
** Increased right ventricular wall thickness
*** Left ventricular [[diastolic dysfunction]]
** [[Tachycardia]]
***[[Increased right ventricular wall thickness]]
***[[Tachycardia]]
 
===Prognosis===


==Prognosis==
* Cardiac amyloidosis is a [[Chronic (medical)|chronic]] and progressive condition.
Cardiac amyloidosis is a chronic and progressive condition. A cardiologist may estimate the prognosis according to the thickness of the [[left ventricle]] and to the degree of restriction in the heart (diastolic dysfunction). Cardiac involvement is the most important predictor of survival in patients with AL amyloidosis.
* A [[Cardiology|cardiologist]] may estimate the [[prognosis]] according to the thickness of the [[left ventricle]] and to the degree of restriction in the [[heart]] (diastolic dysfunction).  
* The extent of cardiac involvement is the most important predictor of survival in patients with [[AL amyloidosis]].<ref name="pmid10319082" />


===Mayo Staging System===
===Mayo Staging System===
Studies have shown that cardiac torponin T and N-terminal proBNP are powerful prognostic indicators in AL amyloidosis. Based on the combined levels of both the indicators a staging system has been developed for risk stratification of patients with AL amyloidosis. Two prognostic models for risk stratification were designed using threshold values for torponins and NT-proBNP. The threshold values used for the markers were: NT-proBNP <332 ng/L, cTnT <0.035 μ<g/L, and cTnI <0.1 <μg/L.<ref name="pmid15365071">{{cite journal |author=Dispenzieri A, Gertz MA, Kyle RA, ''et al.'' |title=Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis |journal=[[Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology]] |volume=22 |issue=18 |pages=3751–7 |year=2004 |month=September |pmid=15365071 |doi=10.1200/JCO.2004.03.029 |url=}}</ref><ref name="pmid15044258">{{cite journal |author=Dispenzieri A, Gertz MA, Kyle RA, ''et al.'' |title=Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation |journal=[[Blood]] |volume=104 |issue=6 |pages=1881–7 |year=2004 |month=September |pmid=15044258 |doi=10.1182/blood-2004-01-0390 |url=}}</ref>
 
* Studies have shown that cardiac troponin T and N-terminal proBNP are powerful prognostic indicators in AL amyloidosis.  
* Based on the combined levels of both the indicators, a staging system has been developed for risk stratification of patients with AL amyloidosis.  
* Two prognostic models for risk stratification were designed using threshold values for troponins and NT-proBNP.  
* The threshold values used for the markers were: NT-proBNP < 332 ng/L, cTnT < 0.035 μg/L, and cTnI <0.1 μg/L.<ref name="pmid15365071">{{cite journal |author=Dispenzieri A, Gertz MA, Kyle RA, ''et al.'' |title=Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis |journal=[[Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology]] |volume=22 |issue=18 |pages=3751–7 |year=2004 |month=September |pmid=15365071 |doi=10.1200/JCO.2004.03.029 |url=}}</ref><ref name="pmid15044258">{{cite journal |author=Dispenzieri A, Gertz MA, Kyle RA, ''et al.'' |title=Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation |journal=[[Blood]] |volume=104 |issue=6 |pages=1881–7 |year=2004 |month=September |pmid=15044258 |doi=10.1182/blood-2004-01-0390 |url=}}</ref>


{| class="wikitable" border="2"
{| class="wikitable" border="2"
Line 51: Line 68:
'''Updated Staging System'''
'''Updated Staging System'''


In 2009 another staging system was proposed which incorporates serum free light chain (serum FLC) levels into the Mayo staging system.   
* In 2009 another staging system was proposed which incorporates serum free light chain (serum FLC) levels into the Mayo staging system.   
 
* The threshold values used for the table below are:
The threshold values used for the table below are:
** NT-proBNP <332 ng/L
 
** cTnT <0.035 μ<g/L
NT-proBNP <332 ng/L
** Serum FLC <500mg/L
 
cTnT <0.035 μ<g/L
 
Serum FLC <500mg/L.


{| class="wikitable" border="2"
{| class="wikitable" border="2"

Latest revision as of 03:32, 4 November 2019

Cardiac amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiac Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac amyloidosis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac amyloidosis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac amyloidosis natural history, complications and prognosis

CDC onCardiac amyloidosis natural history, complications and prognosis

Cardiac amyloidosis natural history, complications and prognosis in the news

Blogs on Cardiac amyloidosis natural history, complications and prognosis

Directions to Hospitals Treating Cardiac amyloidosis

Risk calculators and risk factors for Cardiac amyloidosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]; Cafer Zorkun, M.D., Ph.D. [4]; Lakshmi Gopalakrishnan, M.B.B.S. [5]

Overview

The presence or absence of cardiac involvement with amyloid is the most important prognostic factor. Untreated cardiac amyloidosis is associated with a very poor prognosis and a high mortality rate. The most common cardiac complications include heart failure, sudden cardiac death due to electromechanical dissociation and pericardial effusion.

Natural History, Complications, and Prognosis

Natural History

Complications

The following are the complications of cardiac amyloidosis:

Prognosis

  • Cardiac amyloidosis is a chronic and progressive condition.
  • A cardiologist may estimate the prognosis according to the thickness of the left ventricle and to the degree of restriction in the heart (diastolic dysfunction).
  • The extent of cardiac involvement is the most important predictor of survival in patients with AL amyloidosis.[1]

Mayo Staging System

  • Studies have shown that cardiac troponin T and N-terminal proBNP are powerful prognostic indicators in AL amyloidosis.
  • Based on the combined levels of both the indicators, a staging system has been developed for risk stratification of patients with AL amyloidosis.
  • Two prognostic models for risk stratification were designed using threshold values for troponins and NT-proBNP.
  • The threshold values used for the markers were: NT-proBNP < 332 ng/L, cTnT < 0.035 μg/L, and cTnI <0.1 μg/L.[14][15]
Stage NT-proBNP cTnT/cTnI Median Survival (months)
Stage I Low Low 26.4 - 27.2
Stage II Low or Elevated Elevated or Low 10.5 - 11.1
Stage III Elevated Elevated 3.5 - 4.1

Updated Staging System

  • In 2009 another staging system was proposed which incorporates serum free light chain (serum FLC) levels into the Mayo staging system.
  • The threshold values used for the table below are:
    • NT-proBNP <332 ng/L
    • cTnT <0.035 μ<g/L
    • Serum FLC <500mg/L
Stage NT-proBNP cTnT Serum FLC
Stage I Normal Normal Low
Stage II High Normal Low
Stage III High Normal High
Stage IV High High High

Mortality increased as the stage increased.


Prognosis Based on Pathologic Findings

The presence of nodular deposits, thick perimyocytic layers of amyloid, and small myocyte diameters on endomyocardial biopsy are associated with a worse prognosis. [16]

References

  1. ↑ 1.0 1.1 Gertz MA, Lacy MQ, Dispenzieri A (1999). "Amyloidosis: recognition, confirmation, prognosis, and therapy". Mayo Clinic Proceedings. Mayo Clinic. 74 (5): 490–4. doi:10.4065/74.5.490. PMID 10319082. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
  2. ↑ Shah S, Dungu J, Dubrey SW (2013). "Senile cardiac amyloidosis: an underappreciated cause of heart failure". BMJ Case Reports. 2013. doi:10.1136/bcr-2012-007635. PMID 23391947.
  3. ↑ Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz MA (2013). "Left ventricular device implantation for advanced cardiac amyloidosis". The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation. 32 (5): 563–8. doi:10.1016/j.healun.2013.01.987. PMID 23474361. Unknown parameter |month= ignored (help)
  4. ↑ Edler C, Saeger W, Orth U, Braun C, Wulff B, Sperhake J (2012). "[Hereditary cardiac amyloidosis with transthyretin mutations. A cause of sudden death ]". Herz (in German). 37 (4): 456–60. doi:10.1007/s00059-011-3566-9. PMID 22301727. Unknown parameter |month= ignored (help)
  5. ↑ 5.0 5.1 Mugnai G, Cicoira M, Rossi A, Vassanelli C (2011). "Syncope in cardiac amyloidosis and chronic ischemic heart disease: A case report". Experimental and Clinical Cardiology. 16 (2): 51–3. PMC 3126684. PMID 21747665.
  6. ↑ 6.0 6.1 Brodarick S, Paine R, Higa E, Carmichael KA (1982). "Pericardial tamponade, a new complication of amyloid heart disease". The American Journal of Medicine. 73 (1): 133–5. PMID 7091168. Unknown parameter |month= ignored (help)
  7. ↑ Navarro JF, Rivera M, Ortuño J (1992). "Cardiac tamponade as presentation of systemic amyloidosis". International Journal of Cardiology. 36 (1): 107–8. PMID 1428240. Unknown parameter |month= ignored (help)
  8. ↑ Yunis NA, Petrasko MS, Cannistra LB (2000). "An Elderly Man With Progressive Dyspnea on Exertion and Atrial Fibrillation as Manifestations of Senile Cardiac Amyloidosis". The American Journal of Geriatric Cardiology. 9 (2): 69–72. PMID 11416540. Unknown parameter |month= ignored (help)
  9. ↑ Cheng Z, Zhu K, Tian Z, Zhao D, Cui Q, Fang Q (2013). "The findings of electrocardiography in patients with cardiac amyloidosis". Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. 18 (2): 157–62. doi:10.1111/anec.12018. PMID 23530486. Unknown parameter |month= ignored (help)
  10. ↑ Lin G, Dispenzieri A, Brady PA (2010). "Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death". European Heart Journal. 31 (12): 1538. doi:10.1093/eurheartj/ehp592. PMID 20061577. Unknown parameter |month= ignored (help)
  11. ↑ Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH (1997). "Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement". Journal of the American College of Cardiology. 30 (4): 1046–51. PMID 9316537. Unknown parameter |month= ignored (help)
  12. ↑ Feng D, Syed IS, Martinez M; et al. (2009). "Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis". Circulation. 119 (18): 2490–7. doi:10.1161/CIRCULATIONAHA.108.785014. PMID 19414641. Unknown parameter |month= ignored (help)
  13. ↑ Feng D, Edwards WD, Oh JK; et al. (2007). "Intracardiac thrombosis and embolism in patients with cardiac amyloidosis". Circulation. 116 (21): 2420–6. doi:10.1161/CIRCULATIONAHA.107.697763. PMID 17984380. Unknown parameter |month= ignored (help)
  14. ↑ Dispenzieri A, Gertz MA, Kyle RA; et al. (2004). "Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22 (18): 3751–7. doi:10.1200/JCO.2004.03.029. PMID 15365071. Unknown parameter |month= ignored (help)
  15. ↑ Dispenzieri A, Gertz MA, Kyle RA; et al. (2004). "Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation". Blood. 104 (6): 1881–7. doi:10.1182/blood-2004-01-0390. PMID 15044258. Unknown parameter |month= ignored (help)
  16. ↑ Arbustini E, Merlini G, Gavazzi A; et al. (1995). "Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients". American Heart Journal. 130 (3 Pt 1): 528–36. PMID 7661071. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources CME Category::Cardiology

Retrieved from "https://www.wikidoc.org/index.php?title=Cardiac_amyloidosis_natural_history,_complications_and_prognosis&oldid=1587837"